Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
William L Dahut, James L Gulley, Philip M Arlen, et al.
The Journal of Urology
|
January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
William D Figg, Maha H Hussain, James L Gulley, et al.
The Journal of Urology
|
August 26, 2021
Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
Cheyenne Williams, Michael Ahdoot, Michael A Daneshvar, et al.
The Journal of Urology
|
October 11, 2021
Reply by Authors
Cheyenne Williams, Michael Ahdoot, Michael A Daneshvar, et al.
The Journal of Urology
|
August 21, 2007
Clinical safety of a viral vector based prostate cancer vaccine strategy
Philip M Arlen, Lisa Skarupa, Mary Pazdur, et al.
European Urology Focus
|
September 11, 2018
A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study
J Kellogg Parsons, Peter A Pinto, Christian P Pavlovich, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
Edward Messing, Jason R Gee, Daniel R Saltzstein, et al.
The New England Journal of Medicine
|
March 5, 2020
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Michael Ahdoot, Andrew R Wilbur, Sarah E Reese, et al.
BJU International
|
November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer
Fatima H Karzai, Andrea B Apolo, Liang Cao, et al.
The Journal of Urology
|
June 28, 2021
The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy
Cheyenne Williams, Nabila R Khondakar, Michael A Daneshvar, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
William L Dahut, James L Gulley, Philip M Arlen, et al.
The Journal of Urology
|
January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
William D Figg, Maha H Hussain, James L Gulley, et al.
The Journal of Urology
|
August 26, 2021
Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
Cheyenne Williams, Michael Ahdoot, Michael A Daneshvar, et al.
The Journal of Urology
|
October 11, 2021
Reply by Authors
Cheyenne Williams, Michael Ahdoot, Michael A Daneshvar, et al.
The Journal of Urology
|
August 21, 2007
Clinical safety of a viral vector based prostate cancer vaccine strategy
Philip M Arlen, Lisa Skarupa, Mary Pazdur, et al.
European Urology Focus
|
September 11, 2018
A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study
J Kellogg Parsons, Peter A Pinto, Christian P Pavlovich, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
Edward Messing, Jason R Gee, Daniel R Saltzstein, et al.
The New England Journal of Medicine
|
March 5, 2020
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis
Michael Ahdoot, Andrew R Wilbur, Sarah E Reese, et al.
BJU International
|
November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer
Fatima H Karzai, Andrea B Apolo, Liang Cao, et al.
The Journal of Urology
|
June 28, 2021
The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy
Cheyenne Williams, Nabila R Khondakar, Michael A Daneshvar, et al.
Page
of 4